Nordea Selects Sprinklr to Help Transform Banking Experiences Across Digital Channels
8.12.2020 12:00:00 EET | Business Wire | Press release
Sprinklr, the Customer Experience Management (CXM) platform for modern enterprises, today announced that Nordea, the largest financial services group in Northern Europe, is expanding its use of Sprinklr to deliver digital, personalized banking experiences.
After replacing legacy systems with Sprinklr three years ago because it needed a scalable platform, Nordea has grown its partnership with Sprinklr and is now leveraging four Sprinklr products to create a collaborative, company-wide digital banking strategy.
The Challenge: Growing Company, Changing Customer Behavior & Siloed Reporting
Corporate growth combined with a substantial increase in digital engagement, undefined marketing goals, and disconnected teams created an opportunity for Nordea to develop a strategic digital vision with strong execution capabilities.
The Solution: A Company-Wide Digital Banking Strategy on Sprinklr
Nordea’s marketing team, customer service department, and agencies collaborate in one Sprinklr platform.
With Sprinklr Modern Advertising , Nordea has a single source of truth for agencies and in-house teams to view real-time ad reporting data.
With benchmarking in Sprinklr Modern Research , Nordea can understand where they stand compared to competitors across countries, and can track trending topics and themes in Swedish, Norwegian, Finnish, Danish, and English. Nordea also works with Sprinklr to improve sentiment tracking for Nordic languages.
With Sprinklr Modern Care, the company has dramatically improved the efficiency of their support team. Nordea can use Sprinklr to easily understand if customers are asking questions about specific services – such as a business loan – and quickly connect them to the relevant care agent.
With Sprinklr Modern Engagement, Nordea has one content calendar to collaborate, publish, and plan marketing and engagement campaigns across Twitter, Facebook, Instagram, LinkedIn, and YouTube and answer inquiries on Google My Business and Trustpilot.
Comments on the News:
“Nordea is committed to being the bank of the future that our customers need,” said Elizabeth Fjellerup, Group CMO at Nordea. “Sprinklr provides us with a single platform to enhance every customer experience while empowering our teams to work together with the insights they need to make smart decisions.”
“Nordea is driving digital transformation forward within the financial services industry,” said Pavitar Singh, Chief Technology Officer, Sprinklr. “By implementing a single, companywide Sprinklr platform, Nordea has a clear understanding of its marketing and customer service performance along with deep customer insight. We’re proud to support Nordea’s commitment to delivering an easy digital banking experience.”
Additional Resources:
- Request a Sprinklr demo.
- Read Sprinklr Customer Stories.
About Sprinklr
Sprinklr (@Sprinklr) is the world’s leading Customer Experience Management (CXM) platform. We help organizations reach, engage and listen to customers across 26 social channels, 11 messaging channels, and hundreds of millions of forums, blogs, and review sites. Sprinklr is a global company with 1,900 employees helping the world’s most valuable enterprises make their customers happier.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005160/en/
Contact information
Rachel Alvarez
PR@Sprinklr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom